Comparative evaluation of efficacy of DFDBA and DFDBA enriched with Vitamin D3 in alveolar socket preservation A Clinical Radiographic and Histologic study - NIL

Start Date02 Jan 2026

Sponsor / Collaborator-

NCT07269457

/ Not yet recruitingPhase 2IIT

Vitamin D3 for Moderate to Mild Traumatic Brain Injury: A Randomized Trial on Inflammation and Recovery (VIMOT)

This study is a Phase II, randomized, quadruple-blinded, placebo-controlled clinical trial designed to test whether vitamin D₃ supplementation can improve recovery after mild-to-moderate traumatic brain injury (TBI) in adults.
Traumatic brain injury often leads to inflammation and poor neurological outcomes, and many patients are vitamin D-deficient. Vitamin D₃ is a safe, widely available supplement that may reduce inflammation and support brain recovery.
A total of 240 adults (18-65 years) with mild-to-moderate TBI will be enrolled at Lagos State University Teaching Hospital, Nigeria. Participants will be assigned to one of four groups:
Group A (Deficient + High-Dose D₃): 40,000 IU loading dose, then 4,000 IU daily for 3 weeks Group B (Deficient + Standard-Dose D₃): 2,000 IU daily for 3 weeks Group C (Sufficient + Standard-Dose D₃): 2,000 IU daily for 3 weeks Group D (Sufficient + Placebo): placebo daily for 3 weeks All groups will be followed for 24 weeks. Blood tests at baseline, week 1, week 2, and week 4 will measure inflammation. Neurological recovery will be assessed at weeks 4, 12, and 24 using the Glasgow Outcome Scale-Extended (GOS-E) and Modified Rankin Scale (mRS).
The main outcomes are changes in inflammatory markers. Secondary outcomes include mortality, functional recovery, hospital stay, safety, and cost-effectiveness.
The results may identify a low-cost, scalable treatment to improve outcomes after TBI, especially in low-resource settings.

Start Date02 Jan 2026

Sponsor / Collaborator

Lagos State University

100 Clinical Results associated with Colecalciferol

100 Translational Medicine associated with Colecalciferol

100 Patents (Medical) associated with Colecalciferol

20,593

Literatures (Medical) associated with Colecalciferol

01 Apr 2026·TALANTA

Determination of vitamin D and its metabolites using capillary dried blood microsampling: are we there yet?

Review

Author: Van Uytfanghe, Katleen ; Ghesquière, Rosalie ; Stove, Christophe P ; Heughebaert, Liesl

Dried blood microsampling presents a promising alternative to conventional venous sampling for the quantification of 25-hydroxyvitamin D (25-(OH)D), the established biomarker for assessing vitamin D (vit D) status. Its minimally invasive nature, ease of collection and simplified logistics render microsampling particularly attractive for large-scale epidemiological research employing home-based or remote sampling. Performing such studies is increasingly relevant, as a multitude of diseases have been linked to an inadequate vit D status and, thus, more epidemiological biomarker data are needed to further assess its potential impact. While issues related to the analytical sensitivity and specificity of dried blood microsampling for 25-(OH)D determination have been recognized and addressed to a large extent in literature, several important practical and methodological challenges still hinder broader implementation of this technique. Following an overview of the currently available liquid chromatography-tandem mass spectrometry-based methods for the dried blood-based analysis of 25-(OH)D, this review highlights key remaining pitfalls, including (i) the evaluation of a method's robustness, (ii) challenges related to the interpretation of 25-(OH)D results derived from dried blood microsamples, and (iii) the current lack of specific dried blood microsampling-based standardization programs for 25-(OH)D. Understanding and addressing these knowledge gaps is crucial to ensure the reliability and interpretability of 25-(OH)D measurements obtained via dried blood microsampling.

01 Apr 2026·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

HMGA2 inhibits Pink1-mediated mitophagy and promotes vascular calcification

Article

Author: Yao, Yuyu ; Xiao, Shengjue ; Liu, Naifeng ; Yang, Yiqing ; Chen, Zhengdong ; Ren, Liqun

Mitochondrial dysfunction is implicated in the development of vascular calcification, whereas protective mitophagy helps to hinder its progression. HMGA2 plays a pivotal role in regulating mitochondrial integrity and mitophagy. However, the precise impact of HMGA2-controlled mitophagy on vascular calcification remains unclear. In our study, we observed elevated HMGA2 expression during both Vitamin D3-induced aortic calcification in mice and β-GP-induced calcification of mouse aortic vascular smooth muscle (MOVAS). Additionally, we identified dynamic changes in mitophagy in MOVAS and demonstrated that HMGA2 knockdown promoted mitophagy, exerting a protective effect against vascular calcification in both in vivo and in vitro settings. Preconditioning with the autophagy inhibitor chloroquine diminished the protective effect of HMGA2 knockdown on aortic calcification in mice by inhibiting mitophagy. Furthermore, we observed an increase in cytoplasmic HMGA2 levels in MOVAS following vascular calcification, along with its binding to PTEN induced kinase 1 (Pink1) in the cytoplasm. This affects the distribution of Pink1, which cannot be transferred to the mitochondrial outer membrane to initiate mitophagy. Subsequently, silencing Pink1 exacerbated mitochondrial damage and apoptosis by inhibiting mitophagy, thereby promoting vascular calcification in β-GP-treated MOVAS. Our results indicated that cytosolic HMGA2 bound to Pink1, inhibiting mitophagy by impeding Pink1's relocation from the cytosol to the mitochondria, thereby reducing mitophagy activation, inducing apoptosis, ultimately accelerating the transition of MOVAS to an osteoblastic phenotype and calcium deposition. In conclusion, inducing mitophagy pharmacologically by targeting HMGA2 may represent a promising therapeutic approach for managing vascular calcification.

01 Apr 2026·BIOPHYSICAL CHEMISTRY

Structural and functional insights into Vitamin D receptor mutations: An in-silico investigation of polymorphism-induced resistance

Article

Author: Lohani, Mohtashim ; Dar, Sajad Ahmad ; Jawed, Arshad ; Ahmad, Iffat Zareen ; Aqil, Farrukh ; Khamjan, Nizar Ahmad ; Beigh, Saba ; Khan, Saif

Vitamin D is critical for calcium homeostasis, bone health, and immune regulation via the Vitamin D Receptor. Mutations in the ligand-binding domain and DNA-binding domain can disrupt ligand interactions, causing biologically active metabolite of vitamin D [1α,25-dihydroxyvitamin D3 (calcitriol)] resistance and clinical complications such as hereditary rickets and immune dysregulation. This study explored the structural and functional effects of VDR missense mutations using computational approaches. An AlphaFold-generated VDR model incorporated selected mutations from 503 reported variants, of which 62 were likely pathogenic. Ten LBD mutations were analyzed. Molecular docking assessed Vitamin D3 binding, while molecular dynamics simulations, Root Mean Square Deviation, Radius of Gyration, and Principal Component Analysis evaluated structural stability. CASTp analyses identified key residues in the binding pocket, and downstream non-genomic pathways were assessed to interpret functional effects. Mutations R → H and R → L at position 274, and H → Q at position 305, exhibited minimal RMSD and Rg fluctuations, indicating stable protein conformations. Docking revealed reduced binding affinities (-8.9, -8.8, -9.0 kcal/mol) relative to wild-type (-9.9 kcal/mol), suggesting altered ligand-binding geometry. Other mutations showed greater structural deviations, indicating potential impairment of receptor function. Functional analysis suggested disruption of signaling essential for calcium homeostasis, bone mineralization, and immune regulation. These results demonstrate that missense mutations in the VDR LBD compromise Vitamin D3 binding and receptor stability, contributing to resistance and related skeletal and immune abnormalities. Computational modeling offers a framework to identify pathogenic variants and guide therapeutic strategies, including small molecules, peptide therapies, CRISPR-Cas9 editing, or Vitamin D analogs to restore receptor function and improve clinical outcomes.

161

News (Medical) associated with Colecalciferol

30 Dec 2025

·www.sciencedaily.com

Why your vitamin D supplements might not be working

A randomized trial from Vanderbilt-Ingram Cancer Center reveals that magnesium may be the missing key to keeping vitamin D levels in balance. The study found that magnesium raised vitamin D in people who were deficient while dialing it down in those with overly high levels—suggesting a powerful regulating effect. This could help explain why vitamin D supplements don’t work the same way for everyone and why past studies linking vitamin D to cancer and heart disease have produced mixed results.Researchers at Vanderbilt-Ingram Cancer Center report that magnesium plays a key role in regulating vitamin D levels in the body. In a randomized clinical trial, magnesium increased vitamin D in people who were deficient, while reducing levels in those who already had high amounts. The findings suggest magnesium helps keep vitamin D within a healthy range. The study, published in The American Journal of Clinical Nutrition, adds clarity to long-standing debates about vitamin D's links to colorectal cancer and other diseases. These questions have gained attention due to mixed results from major studies, including the VITAL trial. The new findings also reinforce earlier research from 2013 by the same team, which found that people with low magnesium intake often had low vitamin D levels as well. New Evidence of a Regulating Effect Beyond confirming earlier observations, the trial uncovered an additional insight. Magnesium did not simply raise vitamin D across the board. Instead, it appeared to act as a regulator, lowering vitamin D levels in participants whose levels were already high. This is the first clinical evidence suggesting magnesium may help optimize vitamin D levels rather than just increase them, which could be important for reducing disease risk linked to vitamin D imbalance. Qi Dai, MD, PhD, Ingram Professor of Cancer Research and lead author of the study, explained that the healthiest vitamin D range appears to fall in the middle of a U-shaped curve. Previous observational studies have linked this middle range to the lowest risk of cardiovascular disease. Vitamin D Research Remains Mixed Despite earlier findings, vitamin D did not show a clear link to cardiovascular disease in the recent VITAL trial. Dai and co-author Martha Shrubsole, PhD, a research professor of Medicine in the Division of Epidemiology, are now examining whether magnesium could help explain these inconsistent results. Their work is part of the ongoing Personalized Prevention of Colorectal Cancer Trial. "There's a lot of information being debated about the relationship between vitamin D and colorectal cancer risk that is based upon observational studies versus clinical trials," Shrubsole said. "The information is mixed thus far." Why Magnesium May Matter More Than Expected The researchers turned their attention to magnesium after noticing that vitamin D supplements do not work equally well for everyone. Some people fail to raise their vitamin D levels even when taking high doses. "Magnesium deficiency shuts down the vitamin D synthesis and metabolism pathway," Dai said. The study included 250 adults considered at higher risk for colorectal cancer, either due to known risk factors or because they had previously had a precancerous polyp removed. Participants received either magnesium supplements or a placebo, with dosages tailored to their usual dietary intake. Magnesium Deficiency Is Common in the U.S. Shrubsole noted that vitamin D insufficiency is widely recognized as a public health concern in the United States, and many patients are advised to take supplements based on blood test results. "Vitamin D insufficiency is something that has been recognized as a potential health problem on a fairly large scale in the U.S.," Shrubsole said. "A lot of people have received recommendations from their health care providers to take vitamin D supplements to increase their levels based upon their blood tests. In addition to vitamin D, however, magnesium deficiency is an under-recognized issue. Up to 80 percent of people do not consume enough magnesium in a day to meet the recommended dietary allowance (RDA) based on those national estimates." Food Sources of Magnesium Shrubsole emphasized that magnesium intake in the study matched RDA guidelines and suggested that diet is the best way to increase magnesium levels. Foods rich in magnesium include dark leafy greens, beans, whole grains, dark chocolate, fatty fish such as salmon, nuts and avocados. Additional Vanderbilt co-authors on the study include Xiangzhu Zhu, MD, Hui Nian, PhD, Harvey Murff, MD, MPH, Reid Ness, MD, MPH, Douglas Seidner, MD and Chang Yu, PhD.

Clinical Result

10 Nov 2025

·www.sciencedaily.com

Vitamin D3 breakthrough halves risk of second heart attack

Intermountain Health researchers discovered that customizing vitamin D3 doses for heart attack survivors slashed their risk of another heart attack by 50%. The strategy involved frequent monitoring and dose adjustments to reach ideal vitamin D levels. Traditional studies didn’t track blood levels, missing this critical link. A new study from Intermountain Health in Salt Lake City reports that a personalized vitamin D3 treatment plan for patients who have suffered a heart attack can greatly reduce their chances of another one. In a large randomized clinical trial, researchers found that managing patients' vitamin D levels through a "target-to-treat" approach -- where blood levels were monitored and dosages were adjusted to reach an optimal range -- cut the likelihood of a second heart attack by 50%. The findings were presented on Nov. 9 at the 2025 American Heart Association Scientific Sessions in New Orleans. Encouraging Early Results from Intermountain Researchers These results are very encouraging, said Heidi May, PhD, cardiovascular epidemiologist at Intermountain Health and the study's principal investigator. "We observed no adverse outcomes when giving patients higher doses of vitamin D3 supplementation, and to significantly reduce the risk of another heart attack, which are exciting results," said Dr. May. "We're excited with these results but know we have further work to do to validate these findings." According to researchers, the results carry global importance, as between one-half and two-thirds of people worldwide have low levels of vitamin D. In the past, most individuals received sufficient vitamin D through sunlight exposure. Today, with lifestyle changes and medical advice aimed at reducing skin cancer risk, people spend less time in the sun and must rely more on dietary supplements such as vitamin D3 to maintain healthy levels. From Observation to Precision Treatment Low vitamin D levels have long been linked to poor cardiovascular outcomes in observational studies. However, earlier clinical trials that provided standard supplementation doses failed to show measurable reductions in heart disease risk. Intermountain scientists wanted to test a different idea: rather than giving everyone the same dose, what if supplementation was adjusted to reach a specific, healthy vitamin D level? "Previous studies just gave patients supplementation without regularly checking blood levels of vitamin D to determine what supplementation achieved," said Dr. May. "With more targeted treatment, when we checked exactly how supplementation was working and made adjustments, we found that patients had their risk of another heart attack cut in half." Inside the TARGET-D Clinical Trial The Intermountain study, called the TARGET-D trial, ran from April 2017 to May 2023 and included 630 patients who had suffered a heart attack within a month of enrolling. Participants were followed until March 2025 to monitor cardiovascular outcomes. Patients were randomly assigned to one of two groups: one received no vitamin D management, and the other underwent active, targeted vitamin D3 treatment. The goal for the treatment group was to raise blood vitamin D levels to above 40 nanograms per milliliter (ng/mL). At the start, 85% of participants had vitamin D3 levels below that threshold (<40 ng/mL). Dosing, Monitoring, and Results More than half of the patients receiving targeted therapy required an initial dose of 5,000 international units (IU) of vitamin D3, compared to typical supplement recommendations of 600-800 IU. Vitamin D blood levels were checked annually for those maintaining healthy levels. Patients with lower levels were tested every three months and had their dosage adjusted until reaching the 40 ng/mL target. Afterward, their levels were monitored once a year. Researchers tracked major cardiac events (MACE), including heart attacks, strokes, heart failure hospitalizations, or deaths. Out of 630 participants, 107 experienced such events. While there was no significant difference in the overall risk of MACE between the two groups, the chance of having a second heart attack was cut in half among those receiving targeted vitamin D treatment. Next Steps for Heart and Vitamin D Research Researchers plan to expand their work with a larger clinical trial to confirm and build upon these findings. A larger study group will allow us to more fully evaluate whether targeted vitamin D management can reduce not only repeat heart attacks but also other forms of cardiovascular disease, said Dr. May.

AHAClinical Study

18 Aug 2025

·www.otsuka.co.jp

Research Findings on Skin Condition Fluctuations and Recommended Foods During the Menstrual Cycle

Otsuka Pharmaceutical Co., Ltd. (Otsuka) has women's health as one of its focus areas, including the unique challenges women face throughout different life stages. To support this, we are actively engaged in both research and awareness-raising initiatives. In a recent study published in the Journal of the Japan Society for Menopause and Women's Health, we examined skin changes associated with the menstrual cycle. Our findings categorized these changes by severity and suggested that a jelly drink containing equol, vitamin D, collagen, calcium, and magnesium (the "test food") may help improve skin condition following menstruation. ■ Our Findings Subjective skin evaluations showed that, without the test food, participants experienced improved overall skin conditions from Day 6 to Day 13 of the menstrual cycle. However, these improvements were reduced by the onset of the next cycle. In contrast, when the test food was consumed for six days following menstruation, the skin score from day 6 to day 13 showed a significant enhancement compared to the non-intake period. In addition, the consumption of the test food suppressed the deterioration of skin scores at the beginning of the next menstrual period (Figure 1). Objective assessments further supported this effect, with significant improvements observed in skin smoothness scores from Day 6 to Day 13 (Figure 2). These results indicate that the test food may contribute to better post-menstrual skin condition. Additionally, six days of test food consumption led to an increase in serum 25(OH)D₃, the storage form of vitamin D, which remained elevated for one week after discontinuation. This is the first study to evaluate the effects of a short-term (six-day) intervention using a low dose (20 µg) of vitamin D₃ in Japanese women. Subjective skin evaluations showed that, without the test food, participants experienced improved overall skin conditions from Day 6 to Day 13 of the menstrual cycle. However, these improvements were reduced by the onset of the next cycle. In contrast, when the test food was consumed for six days following menstruation, the skin score from day 6 to day 13 showed a significant enhancement compared to the non-intake period. In addition, the consumption of the test food suppressed the deterioration of skin scores at the beginning of the next menstrual period (Figure 1). Objective assessments further supported this effect, with significant improvements observed in skin smoothness scores from Day 6 to Day 13 (Figure 2). These results indicate that the test food may contribute to better post-menstrual skin condition. Additionally, six days of test food consumption led to an increase in serum 25(OH)D₃, the storage form of vitamin D, which remained elevated for one week after discontinuation. This is the first study to evaluate the effects of a short-term (six-day) intervention using a low dose (20 µg) of vitamin D₃ in Japanese women. ■ Summary: This study investigated the impact of menstrual cycle-related hormonal fluctuations on skin conditions and the potential benefits of foods containing equol, vitamin D, collagen, calcium, and magnesium. A non-blind crossover trial was conducted with 109 premenopausal women who reported experiencing changes in their skin conditions throughout their menstrual cycles. The first day of menstruation was considered Day 1, the participants consumed the test food for 6 consecutive days starting Day 7 during the test food intake period. The skin condition was evaluated subjectively with a self-administered questionnaire and objectively with a physiological assessment. The results demonstrated a significant improvement in the skin condition from Days 6 to 13 during the non-intake period. Conversely, significant deterioration was observed from Day 6 to the beginning of the next menstruation period. During the test food intake period, significant improvements were observed in several areas, including skin roughness. Moreover, these improvements were more pronounced in equol non-producers. This suggests that the consumption of the test food post-menstruation can potentially enhance the skin condition and suppress the deterioration typically experienced at the beginning of the next menstruation cycle. Menopause&Women's Health Jpn 32: 686-698, 2025 Reprint requests: Haruna Miyakawa, Nutraceuticals Research Institute, R&D Headquarters, Nutracenticals Division Otsuka Pharmaceutical Co., Ltd., Reprint requests: Haruna Miyakawa, Nutraceuticals Research Institute, R&D Headquarters, Nutracenticals Division Otsuka Pharmaceutical Co., Ltd., ■ About Equol Equol is a metabolite of soy isoflavone daidzen, which is produced through the action of intestinal bacteria. It is attracting attention for its potential to support women's health and beauty due to its ability to mimic the action of female hormones. However, not everyone can produce equol naturally; studies suggest that only around half of the Japanese population has the gut microbiota necessary to generate it.*1 ■ Otsuka's Initiatives to Promote Women's Health Otsuka has long been committed to addressing the physical and mental changes women experience across different life stages. Our research into menopausal symptoms and premenstrual syndrome (PMS) began in 1996. In 2002, we successfully isolated Lactococcus 20-92, a strain capable of producing equol. Since then, we have conducted extensive domestic and international research on the efficacy and safety of equol derived from fermented soybean sprouts using this strain. In addition to our research, we collaborate with medical professionals to offer seminars and online resources that provide women with accessible, reliable information. Through these efforts, we aim to support women in managing their health and enhancing their quality of life at every stage. Reference：Corporate Website: Women's Health https://www.otsuka.co.jp/en/nutraceutical/about/womens-health/ About Otsuka Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide. For further information, please visit. www.otsuka.co.jp/en/

Clinical Result

100 Deals associated with Colecalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	China	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Hypoparathyroidism	Canada	-	01 Jan 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 3	South Korea	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	Italy	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	Denmark	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	Denmark	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	Denmark	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Rheumatoid Arthritis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Diabetes Mellitus, Type 2	Phase 2	Denmark	University of Aarhus	01 Dec 2008
Complicated urinary tract infection	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05008484 (CTgov)	Phase 2/3	Spinal Cord Injuries	6	NMES+Vitamin D (NMES Plus Vitamin D)	iuttoudfrb(jypaxyzeso) = jvlsofknfx pxwtlziqri (xgclhpgoma, mqzxvabzwf - yupcfbegva) View more	-	23 Jan 2026
				Passive movement+Vitamin D (Passive Movement Plus Vitamin D)	iuttoudfrb(jypaxyzeso) = nsdlbcfnhy pxwtlziqri (xgclhpgoma, mxdxnlypek - ksatkbyayg) View more
NCT01304927 (Pubmed \| Andrology)	Phase 2/3	Infertility	529	Calcium + cholecalciferol supplementation	bjdabmrnlo(chqtvnqpme) = oywbbhfutv bodxuitnxt (obqfvkvkpe )	Negative	14 Jan 2026
				Placebo	bjdabmrnlo(chqtvnqpme) = davvmkbbhf bodxuitnxt (obqfvkvkpe )
NCT02563015 (Pubmed \| Am J Clin Nutr)	Phase 3	Vitamin D Deficiency	98	cholecalciferolvitamin D3 (1000 IU/d of vitamin D3 supplementation)	xrbhxxpunn(kmclohwcdl) = not significantly different between groups ubeqezuuyv (iusutqnmpb ) View more	Positive	01 Nov 2025
				cholecalciferolvitamin D3 (400 IU/d of vitamin D3 supplementation)
NCT04170348 (ViDAS-2, CTgov)	Phase 2	Vitamin a Deficiency \| Asthma \| Vitamin D Deficiency ... View more	58	Daily oral vitamin D3, 3,333 IU (Daily Oral Vitamin D3)	eyhwklvcra(qqauuivkaa) = mtqnpazzwp dtexqgchln (azsfzdwpdw, 2.1) View more	-	24 Sep 2025
				Placebo oral tablet+vitamin D3 (Monthly Bolus Oral Vitamin D3)	eyhwklvcra(qqauuivkaa) = qqbcwzvdlk dtexqgchln (azsfzdwpdw, 2.6) View more
NCT03406897 (POSEIDON, CTgov)	Phase 1/2	Diabetes Mellitus, Type 1 \| Hypoglycemia	27	Omega 3 fatty acid+cholecalciferol (Omega-3 and Vitamin D Combination)	jrkvwhahzq(rjqlcywygp) = uwlouwgnle waqfyhjcam (ypbesghynv, wecfvfpqgv - wbzfqtpygq) View more	-	17 Sep 2025
				cholecalciferol (Vitamin D Only)	jrkvwhahzq(rjqlcywygp) = dlydnckgfb waqfyhjcam (ypbesghynv, tdzwfwtcmy - zsomgxooya) View more
NCT06539260 (Pubmed \| Sci Rep)	Early Phase 1	Rickets vitamin D deficiency	-	Vitamin D3 supplementation	flwargsbto(yeronjszlb) = vxfswwgdtk oqvpuhadfo (mprrkluare ) View more	Positive	11 Jul 2025
NCT04621500 (VitD/RNA-seq, CTgov)	Phase 2	Vitamin D Deficiency \| Prostatic Cancer	60	Allostatic Load+cholecalciferol	gygyncivaq = jqlnswejvj acigvafvns (spdmfwixot, shpfsolxae - kjmsjmzsui) View more	-	04 Jul 2025
NCT04278573 (Pubmed \| J Prim Care Community Health)	Phase 2	Warts	77	Intralesional Vitamin D3 12 000 IU	uzdonqqlub(fgdmtjzgqn): OR = 0.31 (95.0% CI, 0.01 - 10.3), P-Value = 0.51 View more	Negative	01 Jul 2025
				Placebo
NCT01463813 (Finnish Vitamin D Trial, Pubmed \| J Gerontol A Biol Sci Med Sci)	Not Applicable	Well Aging serum 25-hydroxyvitamin D concentration	2,492	Vitamin D3 (Placebo)	xzcikknfpo(wbibplodik) = without statistically significant differences in the event rates between the three arms sdtmkjhcsf (wnrxzqpslb ) View more	Negative	10 Jun 2025
				Vitamin D3 1600 IU/day
NCT04262479 (GADinLADA, CTgov)	Phase 2	Latent Autoimmune Diabetes in Adults	14	recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel+Vitamin D	rtyllwbafa = nukqqkzncf drzvrdrbhd (egsaqzglry, zzkupklofx - nknshjzcud) View more	-	08 Jun 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Colecalciferol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation